Neumora Therapeutics, Inc. Common Stock
NMRANASDAQHealthcare● Active
$1.62
$-0.01(-0.61%)
Market Cap$300160469
P/E Ratio—
52W High$3.65
52W Low$0.716
Neumora Therapeutics, Inc. Common Stock（NMRA）· 现金流量表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · NMRA · 截至 2026-06-10
财务报表
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.24B) | ($0.24B) | ($0.24B) | ($0.13B) | ($0.24B) |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.03B | $0.04B | $0.02B | $0.01B | $0.00B |
| Change in Working Capital | ($0.00B) | $0.02B | ($0.01B) | ($0.01B) | ($0.00B) |
| Net Cash from Operations | ($0.21B) | ($0.18B) | ($0.16B) | ($0.11B) | ($0.08B) |
| Investing Activities | |||||
| Capital Expenditure | $0.00B | $0.00B | ($0.00B) | ($0.00B) | ($0.00B) |
| Purchases of Investments | ($0.09B) | ($0.31B) | ($0.11B) | ($0.23B) | $0.00B |
| Sales of Investments | $0.25B | $0.24B | $0.18B | $0.07B | $0.00B |
| Net Cash from Investing | $0.17B | ($0.07B) | $0.06B | ($0.17B) | ($0.00B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | ($0.00B) | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.06B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | $0.08B | $0.02B | $0.23B | $0.12B | $0.29B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.21B) | ($0.18B) | ($0.16B) | ($0.12B) | ($0.08B) |
| FCF Margin %(computed) | — | — | — | — | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · B
深入了解Neumora Therapeutics, Inc. Common Stock
关于Neumora Therapeutics, Inc. Common Stock（NMRA）现金流量表
Neumora Therapeutics, Inc. Common Stock 2025财年经营活动现金流($0.21B)，自由现金流($0.21B)（FCF利润率—），资本支出$0.00B。
常见问题
NMRA · 4 问Neumora Therapeutics, Inc. Common Stock 2025财年自由现金流($0.21B)，同比down12.8%。
NMRA free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10